Matthias Holdhoff, MD, PhD

Professional Titles

• Co-Director, Brain Cancer Disease Group, Sidney Kimmel Comprehensive Cancer Center

Primary Academic Title

Associate Professor of Oncology

Background

Centers and Institutes

Sidney Kimmel Comprehensive Cancer Center

Videos

• Chemotherapy and Primary Brain Tumors - What You Need to Know

Additional Academic Titles

Associate Professor of Neurology, Associate Professor of Neurological Surgery

Research Interests

Clinical Trials in Primary Brain Cancers, Translational Research in Neuro-Oncology

Research Summary

Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology. His clinical research is concentrated on early phase therapeutic clinical trials in malignant gliomas, including glioblastomas, as well as in primary central nervous system lymphomas. He is leading or participating in multiple brain cancer trials, including within the Adult Brain Tumor Consortium. In addition, he is working on novel biomarkers to assess response and disease activity, including liquid biopsy approaches, in malignant gliomas and primary central nervous system lymphomas.

PubMed

http://www.ncbi.nlm.nih.gov/pubmed/?term=Holdhoff+M

Selected Publications

• Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014 Jul 15;83(3):235-9. PMID:24928128

• Holdhoff M, Guner G, Rodriguez FJ, Hicks JL, Zheng Q, Forman MS, Ye X, Grossman SA, Meeker AK, Heaphy CM, Eberhart CG, De Marzo AM, Arav-Boger R. Absence of Cytomegalovirus in Glioblastoma and Other High-grade Gliomas by Real-time PCR, Immunohistochemistry, and In Situ Hybridization. Clin Cancer Res. 2017 Jun 15;23(12):3150-3157. doi: 10.1158/1078-0432.CCR-16-1490. Epub 2016 Dec 29. PMID: 28034905; PMCID: PMC5474132.

• Holdhoff M, Ye X, Piotrowski AF, Strowd RE, Seopaul S, Lu Y, Barker NJ, Sivakumar A, Rodriguez FJ, Grossman SA, Burger PC. The consistency of neuropathological diagnoses in patients undergoing surgery for suspected recurrence of glioblastoma. J Neurooncol. 2019 Jan;141(2):347-354. doi: 10.1007/s11060-018-03037-3. Epub 2018 Nov 9. PMID: 30414096; PMCID: PMC6342857.

• Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas. Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020. PMID: 28371832; PMCID: PMC5464434.

• Schreck KC, Ranjan S, Skorupan N, Bettegowda C, Eberhart CG, Ames HM, Holdhoff M. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol. 2019

Honors

• Member, Miller Coulson Academy of Clinical Excellence
• Leadership Development Program, ASCO
• Director's Teaching Award in Clinical Science, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Merit Award, Conquer Cancer Foundation
• Young Investigator Award, Conquer Cancer Foundation
• Best Bedside Manner Award, Johns Hopkins Bayview Medical Center
• Alumnus, German Academic Scholarship Foundation (Studienstiftung des deutschen Volkes)